AI Predicting Breast Cancer Risk
Clairity (clairity.com) earns a Brand Analyzer score of 69 out of 100, placing it in the Developing tier among Healthcare brands, SaaS brands. Among 2305 Healthcare brands analyzed, Clairity ranks in the 56th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 98/100, Digital Presence 82/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 52/100, AI Discoverability 71/100, Brand Authority 26/100.
Clairity is a healthcare technology company offering Clairity Breast, the first FDA-authorized AI platform designed to predict a woman's five-year risk of developing breast cancer using only her existing screening mammogram. The platform requires no additional tests and aims to support proactive healthcare decisions through non-invasive risk assessment. Clairity operates in the healthcare and SaaS categories, serving women undergoing routine mammography screenings and healthcare providers such as Beth Israel.
| Brand Name | Clairity |
|---|---|
| Domain | clairity.com |
| Industry | Healthcare, SaaS |
| Main Competitors | iCAD, Hologic, Volpara Health (75/100), Screenpoint Medical, Seno Medical |
Moz Domain Authority 32/100 vs category average 29 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Peace of Mind Starts with Understanding Your Risk Clairity Breast Clairity Breast is the first FDA-authorized AI platform that predicts a woman’s five-year future risk of developin…" (No meta description. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, Facebook, Instagram, GitHub; no detected presence on X (Twitter), YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Clairity scores 28/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Clairity has a weak AI-visibility profile at 28/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (50/100) and its weakest is visibility (15/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 32/100 and thin schema.org structured data.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Clairity offers one identified product: Clairity Breast. Clairity Breast is an FDA-authorized AI platform that uses a woman's existing screening mammogram to predict her five-year future risk of developing breast cancer. The platform requires no additional tests and is designed for use within routine breast cancer screening workflows. It is positioned as a SaaS offering within the healthcare sector, serving both patients and healthcare provider institutions.
Sources: Clairity official site
Clairity's main competitors include iCAD, Hologic, Volpara Health (75/100), Screenpoint Medical, Seno Medical. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Clairity official site
Clairity and Volpara Health are competitors in Healthcare. Brand Analyzer scores Clairity at 69/100 and Volpara Health at 75/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Clairity official site
Popular alternatives to Clairity include iCAD, Hologic, Volpara Health (75/100), Screenpoint Medical, Seno Medical. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Clairity official site
Clairity is a healthcare technology company that operates the first FDA-authorized AI platform for breast cancer risk prediction, known as Clairity Breast. The platform is designed to assess a woman's five-year future risk of developing breast cancer using only her existing screening mammogram, without requiring additional diagnostic tests. Clairity operates in the healthcare and SaaS sectors and positions itself as a pioneering solution for proactive, non-invasive breast cancer risk assessment.
Sources: Clairity official site
Clairity has limited AI-search visibility, scoring 28/100 on Brand Analyzer's AI visibility composite (visibility 15, trust 30, recommendation 50). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Clairity official site
Clairity analyzes standard screening mammograms using artificial intelligence to predict a woman's five-year risk of developing breast cancer. The platform requires no additional tests beyond the routine mammogram a patient has already undergone. By providing precise risk assessments, Clairity aims to empower both women and their healthcare providers to make proactive, informed healthcare decisions. The company describes its offering as providing peace of mind through better understanding of individual cancer risk.
Sources: Clairity official site
Based on the available facts, Clairity Breast holds FDA authorization, which indicates it has passed a regulatory review process by the U.S. Food and Drug Administration. Additionally, the platform is noted to be used by healthcare providers such as Beth Israel, a recognized medical institution. FDA authorization and adoption by established healthcare providers are objective indicators of a degree of credibility and clinical validation, though the known facts do not provide further detail on clinical study outcomes or independent audits.
Sources: Clairity official site
Clairity is known for offering Clairity Breast, described as the first FDA-authorized AI platform that predicts a woman's five-year future risk of developing breast cancer using only her existing screening mammogram. Its key distinction is the combination of FDA authorization and the non-invasive nature of the risk prediction, which relies solely on imaging data already collected during routine screening rather than requiring additional procedures or tests.
Sources: Clairity official site
Clairity scores 50/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Clairity official site
Clairity's platform is designed for two primary user groups: women undergoing routine breast cancer screening mammograms, and healthcare providers involved in breast cancer screening and risk assessment. The known facts specifically identify Beth Israel as an example of a healthcare provider using the platform. The product is intended to support clinical decision-making by giving both patients and their physicians actionable, AI-generated risk data derived from standard mammography imaging.
Sources: Clairity official site
Clairity can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Clairity official site
Ranked closest to Clairity: Sevita (69/100), Civitas Senior Living (69/100), Cleerly (69/100), Colib (69/100).
A step up - brands to learn from: Zipari by mPulse (71/100), Zaina AI (71/100).
Category leader: Dassault Systèmes (95/100).